Description
Original Research
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended- Release) in Adolescents with ADHD
By Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T. Hull, Fatima Chowdhry, Gregory D. Busse, Zare Melyan, Andrew J. Cutler, Robert L. Findling, Stefan Schwabe
